US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alumis Inc.

4.25

-0.0650-1.51%

Volume:135.36K

Turnover:576.72K

Market Cap:230.96M

PE:-0.41

High:4.49

Open:4.28

Low:4.16

Close:4.31

Loading ...

Overview Company News Filings

BRIEF-Alumis And Kaken Pharmaceutical Announce Collaboration And Licensing Agreement For ESK-001 In Dermatology In Japan

Positive Buy Rating for Alumis Inc. Driven by Promising TYK2 Inhibitors and Strategic Advancements

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for Esk-001 in Dermatology in Japan

THOMSON REUTERS

Alumis Inc - to Receive $40 Million Upfront, Potential $140 Million in Milestone Payments

THOMSON REUTERS

Semtech Expands Anterix-Compatible Solutions for Utility Infrastructure

Oppenheimer Sticks to Their Buy Rating for Alumis Inc. (ALMS)

Alumis Price Target Cut to $15.00/Share From $19.00 by HC Wainwright & Co.

Alumis Inc : H.c. Wainwright Cuts Target Price to $15 From $19

THOMSON REUTERS

Alumis price target lowered to $15 from $19 at H.C. Wainwright

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

THOMSON REUTERS

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Acelyrin Adopts Poison Pill as Tang Capital Partners Builds Stake

ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Alumis Price Target Maintained With a $19.00/Share by HC Wainwright & Co.

BRIEF-Alumis Says Phase 3 Onward Program Ongoing With Topline Data Expected In Q1 2026

Alumis Inc - Phase 3 Onward Program Ongoing With Topline Data Expected in Q1 2026

THOMSON REUTERS

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Promising Developments in Alumis Inc.’s Clinical Programs Support Buy Rating

Sector Update: Health Care Stocks Lower Tuesday Afternoon

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ALMS/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALMS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","market":"US","secType":"STK","nameCN":"Alumis Inc.","latestPrice":4.245,"timestamp":1745608693386,"preClose":4.31,"halted":0,"volume":135355,"delay":0,"floatShares":4764683,"shares":54407327,"eps":-10.381567,"marketStatus":"Trading","change":-0.065,"latestTime":"04-25 15:18:29 EDT","open":4.28,"high":4.4884,"low":4.16,"amount":576719.149237,"amplitude":0.076195,"askPrice":4.25,"askSize":166,"bidPrice":4.23,"bidSize":126,"shortable":3,"etf":0,"ttmEps":-10.381567,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745611200000},"marketStatusCode":2,"adr":0,"listingDate":1719547200000,"exchange":"NASDAQ","adjPreClose":4.31,"preHourTrading":{"tag":"盘前","latestPrice":4.36,"preClose":4.31,"latestTime":"09:29 EDT","volume":122,"amount":540.441944,"timestamp":1745587799998},"postHourTrading":{"tag":"盘后","latestPrice":4.42,"preClose":4.31,"latestTime":"19:42 EDT","volume":2133,"amount":9262.9947,"timestamp":1745538170821},"volumeRatio":0.458007,"impliedVol":0.8293,"impliedVolPercentile":0.25},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","floatShares":4764683,"roa":"-87.31%","roe":"-198.66%","lyrEps":-10.381567,"volumeRatio":0.458007,"shares":54407327,"dividePrice":0,"high":4.4884,"amplitude":0.076195,"preClose":4.31,"low":4.16,"week52Low":3.18,"pbRate":"0.89","week52High":13.53,"institutionHeld":0,"latestPrice":4.245,"committee":-0.136986,"eps":-10.381567,"divideRate":0,"volume":135355,"delay":0,"ttmEps":-10.381567,"open":4.28,"prevYearClose":7.86,"prevWeekClose":5,"prevMonthClose":6.14,"prevQuarterClose":6.14,"fiveDayClose":5,"twentyDayClose":4.7,"sixtyDayClose":6.53},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALMS\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522091486","title":"BRIEF-Alumis And Kaken Pharmaceutical Announce Collaboration And Licensing Agreement For ESK-001 In Dermatology In Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2522091486","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522091486?lang=en_us&edition=fundamental","pubTime":"2025-03-25 16:03","pubTimestamp":1742889810,"startTime":"0","endTime":"0","summary":"BRIEF-Alumis And Kaken Pharmaceutical Announce Collaboration And Licensing Agreement For ESK-001 In Dermatology In JapanMarch 25 (Reuters) - Alumis Inc ALMS.O:ALUMIS AND KAKEN PHARMACEUTICAL ANNOUNCE ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nTUABZHV5J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2522627780","title":"Positive Buy Rating for Alumis Inc. Driven by Promising TYK2 Inhibitors and Strategic Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2522627780","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522627780?lang=en_us&edition=fundamental","pubTime":"2025-03-25 14:45","pubTimestamp":1742885156,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Thomas Smith maintained a Buy rating on Alumis Inc. (ALMS – Research Report) yesterday and set a price target of $29.00. T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-buy-rating-for-alumis-inc-driven-by-promising-tyk2-inhibitors-and-strategic-advancements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-buy-rating-for-alumis-inc-driven-by-promising-tyk2-inhibitors-and-strategic-advancements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"gpt_icon":0},{"id":"2522064446","title":"Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for Esk-001 in Dermatology in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2522064446","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522064446?lang=en_us&edition=fundamental","pubTime":"2025-03-25 14:30","pubTimestamp":1742884200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nTUABZHV5J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2522064091","title":"Alumis Inc - to Receive $40 Million Upfront, Potential $140 Million in Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2522064091","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522064091?lang=en_us&edition=fundamental","pubTime":"2025-03-25 14:30","pubTimestamp":1742884200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nTUABZHV5J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2521972300","title":"Semtech Expands Anterix-Compatible Solutions for Utility Infrastructure","url":"https://stock-news.laohu8.com/highlight/detail?id=2521972300","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521972300?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"AirLink XR60 5G Router Now Supports Anterix’s 900 MHz Private Spectrum for Mission-Critical Energy Networks. The ultra-rugged AirLink XR60 5G router delivers versatile, high-performance connectivity, tailored to the demanding needs of utility networks. Supporting both commercial networks and global private LTE and 5G standalone  bands, it now operates on Anterix’s spectrum, standardized under 3GPP Release 18 as band 106. This advancement positions the XR60 as a pivotal tool in driving the adoption of private networks within the utility sector.\"Anterix is thrilled to build on our collaboration with Semtech, a member of the 125+ solutions providers within the Anterix Active Ecosystem. Semtech’s efforts help to expand the reach of our 900MHz private broadband spectrum technology for utilities,\" said Steve Ryan, vice president, ecosystem and partnerships at Anterix. \"With this collaboration, utilities gain access to game-changing solutions purpose-built for secure and resilient operations ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/semtech-expands-anterix-compatible-solutions-120000501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4017","BK4585","SMTC","ALMS","BK4089","BK4141","BK4588","ATEX"],"gpt_icon":0},{"id":"2520473455","title":"Oppenheimer Sticks to Their Buy Rating for Alumis Inc. (ALMS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520473455","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520473455?lang=en_us&edition=fundamental","pubTime":"2025-03-20 20:16","pubTimestamp":1742472975,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Jeff Jones reiterated a Buy rating on Alumis Inc. (ALMS – Research Report) today and set a price target of $26.00. The company’...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-their-buy-rating-for-alumis-inc-alms?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-their-buy-rating-for-alumis-inc-alms?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS","OPY"],"gpt_icon":0},{"id":"2520434194","title":"Alumis Price Target Cut to $15.00/Share From $19.00 by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2520434194","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520434194?lang=en_us&edition=fundamental","pubTime":"2025-03-20 18:31","pubTimestamp":1742466660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2025 06:31 ET (10:31 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"2520434873","title":"Alumis Inc : H.c. Wainwright Cuts Target Price to $15 From $19","url":"https://stock-news.laohu8.com/highlight/detail?id=2520434873","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520434873?lang=en_us&edition=fundamental","pubTime":"2025-03-20 18:23","pubTimestamp":1742466210,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nFWN3Q30MB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2520431796","title":"Alumis price target lowered to $15 from $19 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2520431796","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520431796?lang=en_us&edition=fundamental","pubTime":"2025-03-20 18:10","pubTimestamp":1742465439,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Alumis (ALMS) to $15 from $19 and keeps a Buy rating on the shares following the Q4 report. The ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alumis-price-target-lowered-to-15-from-19-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alumis-price-target-lowered-to-15-from-19-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"gpt_icon":0},{"id":"2520019878","title":"Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2520019878","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520019878?lang=en_us&edition=fundamental","pubTime":"2025-03-20 04:05","pubTimestamp":1742414701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nTUA7CCKHR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2520933601","title":"Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2520933601","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520933601?lang=en_us&edition=fundamental","pubTime":"2025-03-20 04:05","pubTimestamp":1742414700,"startTime":"0","endTime":"0","summary":"– Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated;","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/19/3045800/0/en/Alumis-Reports-Year-End-2024-Financial-Results-and-Highlights-Recent-Achievements.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4516","LU0158827781.USD","BK4588","BK4504","LU0795875086.SGD","LU2089283258.USD","LU2271345857.HKD","CNS","LU1720051017.SGD","LU2347655156.SGD","LU1363072403.SGD","IE00BKVL7J92.USD","LU1074936037.SGD","LU1548497426.USD","ALMS","LU2357305700.SGD","LU2028103732.USD","BK4534","LU0098860793.USD","BK4007","LU0225283273.USD","LU1720051108.HKD","LU0267386448.USD","LU0795875169.SGD","SLE","LU2111349929.HKD","LU0912757837.SGD","LU1668664300.SGD","BK4135","LU0314104364.USD","LU2023251221.USD","BK4127","LU0006306889.USD","LU0106831901.USD","LU0106261372.USD","LU1989772923.USD","LU1162221912.USD","LU2089284900.SGD","LU2133065610.SGD","BK4077","LU0971096721.USD","IE00BZ1G4Q59.USD","LU1732800096.USD","BK4581","LU1732799900.SGD","LU0320765646.SGD","LU1989772840.SGD","BK4585","LU0158827948.USD"],"gpt_icon":0},{"id":"2519350938","title":"Acelyrin Adopts Poison Pill as Tang Capital Partners Builds Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2519350938","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519350938?lang=en_us&edition=fundamental","pubTime":"2025-03-13 20:15","pubTimestamp":1741868100,"startTime":"0","endTime":"0","summary":"Acelyrin said its board approved adopting a limited-duration shareholders' rights plan in response to Tang Capital Partners' accumulation of a stake in the company.The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will become exercisable only if any person acquires 10% or more of Acelyrin's outstanding common stock.Acelyrin said Tang Capital held 8.8% of its outstanding common stock.Tang Capital didn't immediately respond to a request for comment issued through LinkedIn.Poison pills, also called shareholder-rights plans, are legal maneuvers that make it hard for shareholders to build their stakes beyond a set point by triggering an option for others to buy more shares at a discount.Acelyrin in February received an unsolicited indication of interest from Concentra Biosciences, a portfolio company under Tang Capital Management, for an acquisition at","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4139","SLRN","BK4007"],"gpt_icon":0},{"id":"2519887248","title":"ACELYRIN Adopts Limited-Duration Stockholder Rights Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2519887248","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519887248?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:00","pubTimestamp":1741863600,"startTime":"0","endTime":"0","summary":"LOS ANGELES, March 13, 2025  -- ACELYRIN, INC. , a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners’ continued rapid accumulation of 8.8% of ACELYRIN’S outstanding common stock, its Board of Directors has approved the adoption of a limited-duration stockholder rights plan .The ACELYRIN Board and management team continue to engage with stockholders and are focused on maximizing stockholder value.The Rights Plan is effective immediately and will expire on March 12, 2026.ACELYRIN stockholders do not need to take any further action at this time.Guggenheim Securities, LLC is serving as financial advisor to ACELYRIN and Fenwick & West LLP and Paul Hastings LLP are serving as its legal counsel.ACELYRIN, INC.  is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commerciali","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acelyrin-adopts-limited-duration-stockholder-110000068.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4007","ALMS","SLRN"],"gpt_icon":0},{"id":"2518222336","title":"Alumis to Present at Leerink's 2025 Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2518222336","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518222336?lang=en_us&edition=fundamental","pubTime":"2025-03-10 20:00","pubTimestamp":1741608000,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., March  10, 2025  (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimiz","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/10/3039679/0/en/Alumis-to-Present-at-Leerink-s-2025-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS","BK4137","HCSG"],"gpt_icon":0},{"id":"2518240407","title":"Alumis Price Target Maintained With a $19.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2518240407","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518240407?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:49","pubTimestamp":1741607340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2025 07:49 ET (11:49 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"2517419854","title":"BRIEF-Alumis Says Phase 3 Onward Program Ongoing With Topline Data Expected In Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2517419854","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517419854?lang=en_us&edition=fundamental","pubTime":"2025-03-08 22:07","pubTimestamp":1741442831,"startTime":"0","endTime":"0","summary":"BRIEF-Alumis Says Phase 3 Onward Program Ongoing With Topline Data Expected In Q1 2026March 8 (Reuters) - Alumis Inc ALMS.O:ALUMIS INC - PHASE 3 ONWARD PROGRAM ONGOING WITH TOPLINE DATA EXPECTED IN Q1","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250308:nFWN3PR08C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2517441570","title":"Alumis Inc - Phase 3 Onward Program Ongoing With Topline Data Expected in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2517441570","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517441570?lang=en_us&edition=fundamental","pubTime":"2025-03-08 22:03","pubTimestamp":1741442584,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250308:nFWN3PR08C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2517744441","title":"Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2517744441","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517744441?lang=en_us&edition=fundamental","pubTime":"2025-03-08 22:00","pubTimestamp":1741442400,"startTime":"0","endTime":"0","summary":"ESK-001 is a highly selective, next-generation oral tyrosine kinase 2  inhibitor currently under development in moderate-to-severe plaque psoriasis and systemic lupus. Phase 2 OLE data of ESK-001 at 40 mg BID demonstrated sustained or increasing clinical responses through week 52 on PASI 90, PASI 100, and sPGA 0. ESK-001 was generally well-tolerated at one year, with no new safety findings. “We’re excited to see that ESK-001 continues to demonstrate a favorable clinical profile for the potential treatment of moderate-to-severe plaque psoriasis, with the ability to improve clinical outcomes as well as patients’ reported symptoms and quality of life,\" said Dr. Jrn Drappa, Alumis’ Chief Medical Officer. \"We believe in the potential of ESK-001 to fill a critical gap in psoriasis patient care as an oral therapy that is well tolerated and may provide biologic-like clinical responses.\". “These long-term data further support the highly differentiated profile of ESK-001 and reinforce its potent","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/breaking-esk-001-phase-2-140000841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALMS","BK4523","IFN","BK4007"],"gpt_icon":0},{"id":"2517959961","title":"Promising Developments in Alumis Inc.’s Clinical Programs Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2517959961","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517959961?lang=en_us&edition=fundamental","pubTime":"2025-03-05 11:45","pubTimestamp":1741146344,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Thomas Smith has reiterated their bullish stance on ALMS stock, giving a Buy rating on March 3. Thomas Smith’s rating is b...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-developments-in-alumis-inc-s-clinical-programs-support-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-developments-in-alumis-inc-s-clinical-programs-support-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"gpt_icon":0},{"id":"2517489600","title":"Sector Update: Health Care Stocks Lower Tuesday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2517489600","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517489600?lang=en_us&edition=fundamental","pubTime":"2025-03-05 03:00","pubTimestamp":1741114825,"startTime":"0","endTime":"0","summary":"Health care stocks declined Tuesday afternoon, with the NYSE Health Care Index down 0.6% and the Health Care Select Sector SPDR Fund  shedding 0.4%.The iShares Biotechnology ETF  rose less than 0.1%.In corporate news, Walgreens Boots Alliance  is nearing the completion of a go-private deal with Sycamore Partners for around $10 billion, The Wall Street Journal reported late Monday. Walgreens shares jumped 7.3%.UnitedHealth Group  shares rose 2.2% after a retired federal judge in her role as special master issued a recommendation favoring UnitedHealth to the presiding federal judge in a lawsuit brought by the US Department of Justice, which accused the healthcare company of failing to return money it received via the Medicare Advantage program.Acelyrin  and Alumis  reaffirmed Tuesday their commitment to merge in an all-stock deal, as Acelyrin said its board had determined that Concentra Biosciences' unsolicited indication of interest is \"not reasonably expected to result in a superior pr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SG9999014914.USD","LU2361044949.HKD","ALMS","LU0683600562.USD","LU0708994859.HKD","LU1720051017.SGD","LU1267930227.SGD","WBA","LU0238689110.USD","WBA.AU","LU2347655156.SGD","LU0672654240.SGD","LU0234572021.USD","LU1551013342.USD","LU0557290698.USD","LU0823416689.USD","LU0820562030.AUD","IE00BJJMRX11.SGD","IE00B19Z3581.USD","LU1023059063.AUD","LU1291159041.SGD","LU2491050154.USD","SG9999014906.USD","SLRN","SG9999017495.SGD","LU2236285917.USD","LU1506573853.SGD","LU0795875086.SGD","LU1548497426.USD","LU0353189763.USD","LU0310800379.SGD","LU0158827781.USD","SG9999014898.SGD","XLV","LU2552382058.USD","LU0211326755.USD","LU0417517546.SGD","LU1267930730.SGD","LU1854103824.USD","LU1261432733.SGD","LU1988902786.USD","LU0316494557.USD","LU0211328371.USD","IE00BFSS7M15.SGD","LU0661504455.SGD","LU2552382215.SGD","UNH","LU1778281490.HKD","IBB","LU0321505439.SGD"],"gpt_icon":1}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":99,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALMS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-19","symbol":"ALMS","fiscalQuarterEnding":"2024/12","expectedEps":-1.39,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742356800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-13","symbol":"ALMS","fiscalQuarterEnding":"2024/09","expectedEps":-1.64,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-1.73}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALMS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALMS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1738296000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ALMS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ALMS","date":"2025-04-24","current":-0.870937,"percent":0.963351,"low":-5.220865,"twenty":-3.461615,"median":-2.006318,"eighty":-1.170751,"high":-0.660137,"avg":-2.364432,"sd":1.067026,"marketCap":256258510},"quantilePoints":[{"date":"2024-06-28","current":-5.220865,"twenty":-5.220865,"median":-5.220865,"eighty":-5.220865,"marketCap":881360393},{"date":"2024-07-05","current":-3.577828,"twenty":-4.31182,"median":-3.851156,"eighty":-3.577828,"marketCap":603991092},{"date":"2024-07-12","current":-3.798947,"twenty":-4.001025,"median":-3.825051,"eighty":-3.577828,"marketCap":641319297},{"date":"2024-07-15","current":-3.405847,"twenty":-3.980142,"median":-3.798947,"eighty":-3.577828,"marketCap":574958044},{"date":"2024-08-02","current":-4.08515,"twenty":-4.063676,"median":-3.825051,"eighty":-3.577828,"marketCap":689634611},{"date":"2024-08-09","current":-3.930629,"twenty":-4.063676,"median":-3.914533,"eighty":-3.58397,"marketCap":663549141},{"date":"2024-08-16","current":-3.699952,"twenty":-4.025518,"median":-3.855481,"eighty":-3.617622,"marketCap":699416662},{"date":"2024-08-23","current":-3.709695,"twenty":-3.973459,"median":-3.817957,"eighty":-3.659922,"marketCap":701258562},{"date":"2024-08-30","current":-3.67516,"twenty":-3.943506,"median":-3.741353,"eighty":-3.65762,"marketCap":694730166},{"date":"2024-09-06","current":-3.390241,"twenty":-3.930629,"median":-3.739914,"eighty":-3.608539,"marketCap":640870897},{"date":"2024-09-13","current":-3.240587,"twenty":-3.915649,"median":-3.699952,"eighty":-3.511116,"marketCap":612581180},{"date":"2024-09-20","current":-3.272245,"twenty":-3.914533,"median":-3.679477,"eighty":-3.395997,"marketCap":618565543},{"date":"2024-09-27","current":-3.444923,"twenty":-3.859807,"median":-3.655014,"eighty":-3.33556,"marketCap":651207524},{"date":"2024-10-04","current":-2.886598,"twenty":-3.851156,"median":-3.617387,"eighty":-3.295269,"marketCap":545665119},{"date":"2024-10-11","current":-2.961425,"twenty":-3.850149,"median":-3.577828,"eighty":-3.211808,"marketCap":559809977},{"date":"2024-10-18","current":-3.200296,"twenty":-3.817957,"median":-3.47802,"eighty":-3.18015,"marketCap":604964718},{"date":"2024-10-25","current":-3.444923,"twenty":-3.798947,"median":-3.465068,"eighty":-3.200296,"marketCap":651207524},{"date":"2024-10-31","current":-3.231953,"twenty":-3.752872,"median":-3.462191,"eighty":-3.209506,"marketCap":610949081},{"date":"2024-11-08","current":-3.367218,"twenty":-3.741353,"median":-3.447801,"eighty":-3.218715,"marketCap":636518633},{"date":"2024-11-15","current":-2.144174,"twenty":-3.741353,"median":-3.444923,"eighty":-3.209506,"marketCap":511972947},{"date":"2024-11-22","current":-2.15101,"twenty":-3.739051,"median":-3.433411,"eighty":-3.073089,"marketCap":513605166},{"date":"2024-11-29","current":-2.109995,"twenty":-3.736748,"median":-3.419021,"eighty":-3.008623,"marketCap":503811848},{"date":"2024-12-06","current":-1.964163,"twenty":-3.720056,"median":-3.405847,"eighty":-2.970059,"marketCap":468991158},{"date":"2024-12-13","current":-1.989228,"twenty":-3.703849,"median":-3.378729,"eighty":-2.667081,"marketCap":474975964},{"date":"2024-12-20","current":-1.966442,"twenty":-3.691984,"median":-3.312536,"eighty":-2.153744,"marketCap":469535232},{"date":"2024-12-27","current":-1.916313,"twenty":-3.685521,"median":-3.301025,"eighty":-2.142807,"marketCap":457565620},{"date":"2025-01-03","current":-1.873019,"twenty":-3.682067,"median":-3.286635,"eighty":-2.0626,"marketCap":447228227},{"date":"2025-01-10","current":-1.752253,"twenty":-3.67516,"median":-3.266489,"eighty":-2.0029,"marketCap":418392344},{"date":"2025-01-17","current":-1.775039,"twenty":-3.672282,"median":-3.247782,"eighty":-1.966442,"marketCap":423833077},{"date":"2025-01-24","current":-1.497048,"twenty":-3.658468,"median":-3.227637,"eighty":-1.954138,"marketCap":357456138},{"date":"2025-01-31","current":-1.531227,"twenty":-3.654166,"median":-3.211808,"eighty":-1.919959,"marketCap":365617237},{"date":"2025-02-07","current":-1.501605,"twenty":-3.631778,"median":-3.162882,"eighty":-1.882133,"marketCap":358544284},{"date":"2025-02-14","current":-1.162092,"twenty":-3.62163,"median":-3.070787,"eighty":-1.832004,"marketCap":277477367},{"date":"2025-02-21","current":-1.168928,"twenty":-3.613315,"median":-3.018984,"eighty":-1.784609,"marketCap":279109587},{"date":"2025-02-28","current":-1.064112,"twenty":-3.590112,"median":-2.978693,"eighty":-1.743594,"marketCap":254082217},{"date":"2025-03-07","current":-1.162092,"twenty":-3.577828,"median":-2.970059,"eighty":-1.696654,"marketCap":277477367},{"date":"2025-03-14","current":-1.045883,"twenty":-3.561975,"median":-2.844868,"eighty":-1.612801,"marketCap":249729630},{"date":"2025-03-21","current":-0.660137,"twenty":-3.530406,"median":-2.358363,"eighty":-1.527581,"marketCap":194234157},{"date":"2025-03-28","current":-0.869088,"twenty":-3.513232,"median":-2.153288,"eighty":-1.493402,"marketCap":255714436},{"date":"2025-04-04","current":-1.579152,"twenty":-3.504209,"median":-2.144174,"eighty":-1.320049,"marketCap":464638572},{"date":"2025-04-11","current":-1.262952,"twenty":-3.478882,"median":-2.109995,"eighty":-1.320049,"marketCap":371602043},{"date":"2025-04-17","current":-0.937506,"twenty":-3.463917,"median":-2.033661,"eighty":-1.195689,"marketCap":275845147},{"date":"2025-04-24","current":-0.870937,"twenty":-3.461615,"median":-2.006318,"eighty":-1.170751,"marketCap":256258510}],"updateTime":1745572110760}}}